Suppr超能文献

基于透明质烷的关节腔内注射和静脉注射黏弹性补充剂在动物模型中的清除动力学

Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models.

作者信息

Larsen Nancy E, Dursema Holly D, Pollak Cynthia T, Skrabut Eugene M

机构信息

Genzyme Biosurgery, 1125 Pleasant View Terrace, Ridgefield, New Jersey 07657.

出版信息

J Biomed Mater Res B Appl Biomater. 2012 Feb;100(2):457-62. doi: 10.1002/jbm.b.31971. Epub 2011 Nov 21.

Abstract

Clearance of hylan fluid and hylan gel, components of the hyaluronan (HA)-derived viscosupplement hylan G-F 20, following intra-articular injection into normal, healthy rabbits was evaluated. Radiolabeled hylan G-F 20 was injected at a volume of 0.3 mL into both knee joints of 12 rabbits. At sacrifice, synovial fluid, joint tissues, blood, popliteal lymph nodes, liver, spleen, kidney, and lung were analyzed for radioactivity. The half-life of the fluid component, a high-molecular weight hylan, was 1.5 ± 0.2 days while the half-life of the hylan gel component, a crosslinked hylan, was 8.8 ± 0.9 days. There was no radioactivity detected in the blood or the major internal organs following intra-articular injection. A rat model was used to evaluate the clearance of a large intravenous bolus of solubilized hylan gel. No accumulation of hylan gel degradation products was observed in any major organs and the half-life of hylan elimination from the blood was within normal ranges for HA elimination. The dosing used in the nonclinical rabbit intra-articular study was equivalent (v/w) to a single 6 mL dose in humans. These results are consistent with the current clinical data that demonstrates safety and effectiveness of an increased volume of hylan G-F 20 injected into the osteoarthritis knee.

摘要

对透明质酸(HA)衍生的粘弹性补充剂海乐妙(hylan G-F 20)的成分——海乐流体和海乐凝胶,在向正常、健康兔关节腔内注射后的清除情况进行了评估。将放射性标记的海乐妙以0.3 mL的体积注射到12只兔的双侧膝关节中。处死动物时,对滑液、关节组织、血液、腘窝淋巴结、肝脏、脾脏、肾脏和肺进行放射性分析。流体成分(一种高分子量海乐)的半衰期为1.5±0.2天,而海乐凝胶成分(一种交联海乐)的半衰期为8.8±0.9天。关节腔内注射后,在血液或主要内脏器官中未检测到放射性。使用大鼠模型评估了大剂量静脉注射溶解的海乐凝胶的清除情况。在任何主要器官中均未观察到海乐凝胶降解产物的蓄积,且海乐从血液中消除的半衰期在HA消除的正常范围内。非临床兔关节内研究中使用的剂量(体积/体重)相当于人类单次6 mL的剂量。这些结果与目前的临床数据一致,该数据表明向骨关节炎膝关节注射增加剂量的海乐妙具有安全性和有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验